ReviewBiology direct2026
Autochthonous dengue transmission in Europe: epidemiology, mechanisms, and modelling insights.
Review in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue is the most rapidly expanding arboviral infection globally, with rising incidence and widening geographic distribution driven by urbanisation, climate change, vector expansion, and global mobility. Although traditionally confined to tropical and subtropical regions, dengue is increasingly emerging in temperate settings, including Europe. Recent outbreaks in Italy, Spain, and France, together with evidence of under-recognised transmission, indicate a transition from sporadic importation to recurrent autochthonous infection. This shift is facilitated by the establishment of Aedes albopictus, increasing climatic suitability, an increase in case importation from endemic areas and delays in clinical recognition and public health response. MAIN BODY: In non-endemic regions, dengue presents distinct challenges, including low population immunity, limited clinical awareness, and diagnostic constraints that may hinder early detection. While advances in vaccines, particularly TAK-003, and novel vector control strategies such as Wolbachia-based interventions offer new opportunities, their role in Europe remains context-specific and complementary to strengthened surveillance and preparedness systems. Modelling approaches provide valuable decision support but are constrained by data limitations in emerging settings.
conclusionsThe emergence of dengue in Europe should be viewed as an early signal of broader changes in vector-borne disease dynamics. Proactive investment in integrated surveillance, diagnostics, vector control, and targeted vaccination strategies will be essential to mitigate future risk and prevent sustained transmission in non-endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.